Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 May 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History